Field Medical Sets New Standards in Cardiac Care
Instantaneous Ablation Technology in Action
Field Medical, Inc., a pioneering clinical-stage medical technology company specializing in pulsed field ablation (PFA) solutions, has recently unveiled groundbreaking clinical trial data at a prominent event that demonstrates a significant advancement in the treatment of complex cardiac arrhythmias. This presentation occurred during a notable medical symposium.
Presentation of Late Breaking Clinical Trial Data
During a highly anticipated session at a major medical conference, the results of the first-in-human Field PULSE study were revealed. The study was distinguished as a Late Breaking Clinical Trial (LBCT), highlighting its importance in the ongoing development of cardiac care technologies.
Groundbreaking Findings from Field PULSE Study
The Field PULSE study evaluates a novel approach that utilizes high-voltage, sub-second pulsed field waveforms via Field Medical's innovative FieldForce™ Ablation System, a specialized catheter designed for effective energy delivery. This method allows for immediate tissue ablation, providing both efficiency and precision in treatment without the need for prolonged contact between the catheter and tissue.
Benefits of the New Approach
Dr. Vivek Y. Reddy, principal investigator of the Field PULSE study, expressed enthusiasm about the results: "By removing the necessity for sustained tissue-catheter contact, we can achieve point-by-point ablation with remarkable efficiency, allowing for the customization of lesion sets tailored to each patient's needs. This not only enhances procedural efficiency but also offers physicians the flexibility they require during interventions."
Study Highlights and Insights
The study yielded remarkable findings that shed light on the efficacy and safety of this new ablation technique:
- Instantaneous Energy Delivery: Lesions were achieved in less than 200 milliseconds, making rapid point-by-point ablation possible.
- Enhanced Procedural Efficiency: The median time required for bilateral pulmonary vein isolation (PVI) was recorded at an impressive 12.5 minutes, with individual cases completed in as little as 7.7 minutes.
- PVI Durability: The remapping results revealed a progressive enhancement in PVI durability as a result of the optimized waveform.
- By vein: 94.2%
- By patient: 84.6%
- Safety of the Procedure: No serious adverse events related to the device were recorded, and no notable occurrences of acute kidney injury or clinically significant complications were reported.
These advancements mark a significant step forward in Field Medical's commitment to enhancing care for patients facing cardiac arrhythmias, specifically showing excellent potential in treating atrial fibrillation (AF).
Reinforcing a New Paradigm in Ablation Technology
Dr. Steven Mickelsen, founder and chief technology officer of Field Medical, articulated the driving philosophy behind the research: "The results from the Field PULSE study reinforce our strategy to design focal PFA technologies that directly tackle the limitations of current approaches and validate their implementation through robust data results. Our methodology allows for rapid ablation point delivery, minimizing reliance on catheter stability during procedures and lowering the impact of cardiac motion. This creates a consistent platform for addressing complex arrhythmias in innovative ways."
Future Directions as Highlighted at the Symposium
The Field PULSE findings were shared during a dedicated session focused on clinical advancements. The discussions centered around maximizing lesion depth using high-voltage PFA waveforms and showcased the efficacy of the FieldForce Ablation System and catheter in real clinical settings.
Field Medical is poised to continue its role as an innovator in the field of cardiac care, with plans for future presentations and collaborations on the horizon to further expand understanding and implementation of their advanced ablation technologies.
About the FieldForce Ablation System
The FieldForce Ablation System represents a significant achievement in the quest for efficient and safe cardiac treatment options. Built on cutting-edge technology, this focal, contact-sensing PFA system utilizes controlled electric fields delivered through innovative pulsed energy mechanisms, making it suitable for both atrial and ventricular applications.
About Field Medical, Inc.
Established in 2022, Field Medical is a forward-thinking company dedicated to the evolution of pulsed field ablation solutions designed to tackle complex cardiac arrhythmias head-on. Their advanced FieldForce Ablation System integrates innovative energy delivery mechanisms that are tailored to ensure precise and efficient ablation. This approach aligns with their commitment to improving patient outcomes across various cardiac conditions.
Frequently Asked Questions
What is the Field PULSE study about?
The Field PULSE study evaluates a novel high-voltage pulsed field ablation approach to treat complex cardiac arrhythmias effectively.
What are the main advantages of using the FieldForce Ablation System?
This system allows for instantaneous ablation, increased procedural efficiency, and customization of lesion sets without prolonged catheter contact.
Who presented the study data?
Dr. Vivek Y. Reddy, the principal investigator, shared the findings during a significant medical symposium.
What notable findings were reported from the study?
The study demonstrated rapid lesion creation, improved procedural efficiency, and no reported serious adverse effects.
What future developments are anticipated from Field Medical?
Field Medical plans to expand its research and clinical applications, continuing to enhance its innovative ablation technologies.
